Zhejiang Taimei Medical Technology Co., Ltd. (“Taimei Tech”) disclosed a share buyback executed on 26 June 2026 under its Hong Kong mandate.

• Transaction details – Quantity: 29,200 H-shares repurchased on the Hong Kong Stock Exchange. – Price range: HK$6.17 to HK$6.23 per share, with a volume-weighted average of HK$6.2149. – Consideration: HK$0.18 million.

• Impact on share capital – Issued shares (excluding treasury shares) decreased from 199.77 million to 199.74 million, representing a 0.01% reduction. – Treasury shares rose to 849,800 following the buyback. – Total issued share count, including treasury shares, remained unchanged at 200.59 million.

• Repurchase mandate utilisation – Authorised limit: 20.02 million shares (resolution dated 23 June 2026). – Cumulative purchases under the mandate: 428,800 shares, or 0.21% of the company’s issued shares on the mandate date.

• Regulatory considerations – In line with Hong Kong Listing Rules, Taimei Tech is subject to a 30-day moratorium on new share issues or treasury-share sales until 26 July 2026.

The company confirmed that the repurchase complied with all relevant Exchange regulations and the explanatory statement issued on 1 June 2026.